A Phase 3 randomized, double-blind, placebo-controlled trial investigating Baxdrostat for resistant hypertension was published on 2026-01-01. The publication, titled 'Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24),' details the drug's impact on blood pressure.
Background
Baxdrostat is an investigational drug being studied for the treatment of resistant hypertension. Resistant hypertension is defined as blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes, including a diuretic, or controlled blood pressure on four or more antihypertensive agents. This condition represents a significant clinical challenge due to its association with increased cardiovascular risk.
Trial design
The Bax24 study was a Phase 3, randomized, double-blind, placebo-controlled trial. It investigated the effect of Baxdrostat on ambulatory blood pressure in participants diagnosed with resistant hypertension. The trial compared the investigational drug Baxdrostat against a placebo arm, with its primary objective being to assess the drug's impact on ambulatory blood pressure.
What this means
The publication of these Phase 3 trial results for Baxdrostat provides important information regarding its potential role in managing resistant hypertension. Clinicians and researchers will review the detailed findings to understand the drug's efficacy and safety profile in this challenging patient population, where treatment options are often limited. The data will inform future development and potential regulatory submissions for Baxdrostat.
Source
The information regarding the Bax24 trial publication was obtained from PubMed, a public database of biomedical literature. The article, titled 'Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial (Lancet),' was published on 2026-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.